Full Press Release Details
Cellect Receives Russian Patent
Covering any Device and Method Using
Cellect's Flagship Technology - the ApoGraft
PATENT COVERS FIRST-IN-KIND DEVICES
FOR SIMPLE AND ROBUST STEM CELL SELECTION
REPLACING HIGH-COST AND COMPLEX PROCESSES USED TODAY
Dr. Shai Yarkoni, CEO, commented,
"Russia is an multi-billion dollar
market opportunity for Cellect's technology licenses."
Aviv, Israel - June 14, 2017 - Cellect Biotechnology Ltd. (Nasdaq: APOP, TASE: APOP), a developer
of stem cells selection technology, announced today that further to the notices of allowance received from the US patent office,
the Company has received further confirmation for grant of its patent by the Russian patent authorities (Application No. 2014138001)
for a key composition of matter and method of use covering various devices using the ApoGraft for selection of Stem Cells.
Dr. Shai Yarkoni, CEO,
commented, "Russia is an important market for us that we believe represents a multi-billion dollar market opportunity
for Cellect's technology licenses. This patent is a fundamental base for the future commercialization of our
global business and with the US already covered, Russia is the major next country to address. We are aware of the vast stem
cell treatment performed nowadays in Russia and therefore believe that our technology will be well-suited this fast-growing
demand for stem cells. Cellect has seven families of patents and patent applications to protect its core assets for enabling
stem cell regenerative medicine. With this patent, Cellect we believe that has the opportunity to diversify its pipeline and
open up new commercialization routes for additional market segments."
The device is designed to enable cell
selection in a simplified setting by an off-the-shelf product - a solution that currently does not exist and that could
potentially cover a wide range of unmet medical needs.
The devices covered by the patent are essentially
containers (a bag, column, tube, bottle, vial, flask or bioreactor) comprised of a biocompatible material and a biologically active
apoptosis-inducing ligand immobilized to a surface in the inner side of the container. The device is adapted to cell selection
of apoptosis-sensitive cells. Specifically, the patent gives the company full protection against any devices that make use of apoptosis
for cell selection. It also protects the method for using the device.
Such devices, enable selection for
stem-cells and immune cells which support engraftment and negative selection for immune cells which induce graft versus host
disease (GvHD) out of a heterogeneous cell population.
About Cellect Biotechnology Ltd.
Cellect Biotechnology is traded on
both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP"). The
Company has developed a breakthrough technology designed to select stem cells from any given tissue, a technology that aims
to improve a variety of stem cell applications.
The Company's technology is
intended to provide pharma companies, medical research centers and hospitals with tools designed to rapidly select stem
cells in quantity and quality that will enable stem-cell related treatments and procedures. Cellect's technology
is applicable to a wide variety of stem cell-related treatments in regenerative medicine. The Company's current
clinical trials are aimed at the cancer treatment of bone marrow transplantations.
Forward Looking Statements
This press release contains forward-looking
statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the
use of forward-looking words such as "believe", "expect", "intend", "plan", "may",
"should", "could", "might", "seek", "target", "will", "project",
"forecast", "continue" or "anticipate" or their negatives or variations of these words or other
comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking
statements are used in this press release when we discuss our expectation that a patent will be issued based on pending patent
applications, our beliefs about the future integration of our technology into the production procedures of stem cell-based products,
the scope of patent protection, the potential of our technology and its proposed uses. These forward-looking statements and their
implications are based on the current expectations of the management of the Company only, and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results
would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional
research or otherwise. The following factors, among others, could cause actual results to differ materially from those described
in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching
and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may
not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain
or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may
develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate
to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical
trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop
and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to
differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release
speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking
statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable
securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading
"Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2016
filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov. and in the
Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial Officer